CDNA — CareDx, Inc

CareDx, Inc. Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: Increased 39% to $118 million.
• Testing Volume: Up 17% to 54,900 tests.
• Testing Services Revenue: Grew 48% to $91 million, averaging $16.60 per test.
• Patient and Digital Solutions Revenue: Increased 33% to $16 million.
• Lab Products Revenue: Declined 4% to $10 million.
• Non-GAAP Gross Margins: Increased to 73%.
• GAAP Net Income: Reported at $3 million, or $0.05 per share.
• Adjusted EBITDA: Rose over 300% to $19 million.
• Cash Flow: Cash collections increased 52% to $121 million, with $198 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Divestiture of Lab Products: Announced on April 15, aimed at streamlining operations and focusing on precision medicine testing. Expected to close by Q3 2026, providing $170 million in cash.
• Acquisition of Navaris: Announced during the call, targeting solid tumor minimal residual disease (MRD) testing. Navaris has performed over 130,000 tests and is expected to grow 30-40% annually.
• Innovation Pipeline: Progress in cell therapy program Alaheme and expansion of AlloSure into liver transplantation. Launch of HistoMap kidney to enhance biopsy insights.
• Go-to-Market Strategy: Focus on integrating digital solutions into clinical workflows, aiming for 50% of testing volume through Epic-integrated sites by year-end.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $447 million to $465 million, reflecting a 20% year-over-year increase.
• Adjusted EBITDA Guidance: Projected between $43 million and $57 million, a 58% increase year-over-year.
• Testing Volume Expectation: Anticipated between 224,000 and 229,000 tests for the year, a 13% increase.

4. Bad News, Challenges, or Points of Concern

• Lab Products Decline: Revenue from the Lab Products segment declined, indicating potential challenges in that area.
• Market Volatility: Transplant procedure volumes remain sluggish, raising concerns about sustaining double-digit growth in testing volumes.
• Competitive Pressures: The market for molecular testing is competitive, and maintaining a leading position in new areas like MRD will require effective execution and differentiation.

5. Notable Q&A Insights

• Market Access for MRD: The $1.5 billion MRD market is accessible through existing channels, with no new channels needed for growth.
• Digital Solutions Adoption: Approximately 70% of transplant centers utilize at least one CareDx digital solution, indicating strong integration into workflows.
• R&D Efficiency: Navaris operates efficiently, with potential for cost reductions through automation and improved revenue cycle management.
• Transplant Volume Growth: The company is closely monitoring transplant volumes, with some centers showing signs of acceleration, but overall growth remains uncertain.

Overall, CareDx is positioning itself for significant growth through strategic acquisitions and a focus on innovation in precision medicine, despite facing challenges in market conditions and competition.